Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports

Version 1 : Received: 22 February 2023 / Approved: 3 March 2023 / Online: 3 March 2023 (08:30:15 CET)

A peer-reviewed article of this Preprint also exists.

Sadat Larijani, M.; Doroud, D.; Banifazl, M.; Karami, A.; Bavand, A.; Ashrafian, F.; Ramezani, A. A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports. European Journal of Medical Research 2023, 28, doi:10.1186/s40001-023-01531-7. Sadat Larijani, M.; Doroud, D.; Banifazl, M.; Karami, A.; Bavand, A.; Ashrafian, F.; Ramezani, A. A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports. European Journal of Medical Research 2023, 28, doi:10.1186/s40001-023-01531-7.

Abstract

Vaccination against SARS-CoV-2 has significantly contributed to the recent pandemic control. COVID-19 vaccines are available with different platforms and the primary clinical trials results presented acceptable safety profile of the approved vaccines. Nevertheless, the long-term assessment of the adverse events or rare conditions need to be investigated. The present systematic review, aimed at classification of Iranian case reports following COVID-19 immunization. To achieve this goal, the related published case reports were explored via PubMed, Web of Science and Google scholar according to PRISMA guideline and available up to 14th Dec, 2022. Out of 437 explored studies, the relevant data were fully investigated which totally led to 40 studies including 64 case reports with a new onset of a problem. The cases were then classified according to the various items such as the type of adverse event manifestations and COVID-19 vaccine. The reported COVID-19 vaccines in the studied cases included Sinopharm, AstraZeneca, and COVAXIN. The results showed that the adverse events presented in 8 different categories from which cutaneous problems accounted as the most prevalent manifestations (43.7%) in which rare diseases were also screened such as Steven-Johnson syndrome, Morphea and Toxic Epidermal Necrolysis. Notably, almost 60% of the cases had no comorbidities. Moreover, the obtained data revealed nearly half of the incidences occurred after the first dose of injection and the mean duration of improvement after the symptom onset was 18.72±24.69 days. 73% of all the cases were either significantly improved or fully recovered. Although the advantages of COVID-19 vaccination is undoubtedly significant, the high risk individuals including those with a history of serious disease or comorbidities immunodeficiency conditions should be vaccinated with the utmost caution.

Keywords

COVID-19; Vaccination; Adverse event; Case report; Iran

Subject

Medicine and Pharmacology, Pathology and Pathobiology

Comments (5)

Comment 1
Received: 4 October 2023
The commenter has declared there is no conflict of interests.
Comment: I would like to thank the authors to share this preprint.
It was really informative and practical.
I would like to have the revised published version if possible.
Thank you.
+ Respond to this comment
Comment 2
Received: 4 October 2023
The commenter has declared there is no conflict of interests.
Comment: I would like to thank the authors to share this preprint.
How can I have the published one??
+ Respond to this comment
Comment 3
Received: 4 October 2023
Commenter:
The commenter has declared there is no conflict of interests.
Comment: How interesting the side effects were shown.
Good job!
+ Respond to this comment
Comment 4
Received: 22 October 2023
Commenter:
The commenter has declared there is no conflict of interests.
Comment: Amazing facts!
I hope the authors keep going on the issue and report further case reports in such scientific voice.
Fantastic!
+ Respond to this comment
Comment 5
Received: 22 October 2023
Commenter:
The commenter has declared there is no conflict of interests.
Comment: I also would like to keep contact with the authors in future.
Is the article published?
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 5
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.